RespireRx Pharmaceuticals Inc (OTCMKTS:RSPI) Stock Pulls Back a Bit After The Big Jump

RespireRx Pharmaceuticals Inc (OTCMKTS:RSPI) is well known for its work on the development of innovative treatments that are meant for tackling conditions that are brought about by neuronal signalling.

Traders Corner

RSPI  stock is trading below the 20-Day and 50-Day Moving averages of $0.1710 and $0.0206 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0322. The stock is down 35% in the past month.

Announces Publication of Review Article Describing Advances in the Discovery, Development and Commercialization of GABAkines, Including KRM-II-81

Although there was no news about the company on Tuesday, the stock suffered from a sharp selloff and went down by as much as 5%. That being said, it should be noted that the selloff may have been related to the announcement made by the company earlier on in the week on Monday. The company announced on Monday that scientists who are associated with it had their review article published in the journal Pharmacology and Therapeutics.

In this regard it should be noted that the journal in question is a peer reviewed one and hence, the publication of the article is a significant development.

The article that had been published was titled “GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors”. While the news led to a degree of positivity about the stock on the day of the announcement, it seems that the sentiments eventually wore off on Tuesday. It could be interesting to see if the stock can actually bounce back any time soon.

Traders Corner

RSPI stock is trading below the 20-Day and 50-Day Moving averages of $0.1710 and $0.0206 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0322. The stock is down 35% in the past month.